Language

English

Publication Date

1-1-2025

Journal

Frontiers in Immunology

DOI

10.3389/fimmu.2025.1618404

PMID

40808942

PMCID

PMC12343627

PubMedCentral® Posted Date

7-30-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Introduction: Clinical studies of T cells engineered with chimeric antigen receptor (CAR) targeting CD19 in B-cell malignancies have demonstrated that relapse due to target antigen (CD19) loss or limited CAR T cell persistence is a common occurrence. The possibility of such events is greater in solid tumors, which typically display more heterogeneous antigen expression patterns and are known to directly suppress effector cell proliferation and persistence. T cell engineering strategies to overcome these barriers are being explored. However, strategies to simultaneously address both antigen heterogeneity and T cell longevity, while localizing anti-tumor effects at disease sites, remain limited.

Methods: In this study we explore a dual antigen targeting strategy by directing independent CARs against the solid tumor targets PSCA and MUC1. To enhance functional persistence in a tumor-localized manner, we expressed the transgenic IL-7 cytokine and receptor (IL-7Rα) in respective CAR products.

Results: This binary strategy, which incorporates dual antigen targeting with transgenic cytokine support, resulted in enhanced potency, T cell expansion, and durable antitumor effects in a pancreatic tumor model compared to single antigen targeting or dual antigen targeting in absence of the transgenic cytokine support.

Discussion: The transgenic IL-7 armed binary CAR T cell approach could improve the efficacy of CAR-based therapies for solid tumors.

Keywords

Animals, Immunotherapy, Adoptive, Humans, Receptors, Chimeric Antigen, Interleukin-7, Mice, T-Lymphocytes, Mucin-1, Cell Line, Tumor, Antigens, Neoplasm, Pancreatic Neoplasms, Receptors, Antigen, T-Cell, Xenograft Model Antitumor Assays, Receptors, Interleukin-7, Female, Neoplasm Proteins, chimeric antigen receptor, T-cell therapy, IL-7, IL-7R, solid tumor, pancreatic cancer, PSCA, MUC 1

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.